Loading
Epigenetics and DNA Methylation / Cholinesterase and Neurodegenerative Diseases · Journal article
Scientific Reports · August 8, 2026
Encouraging direction, but not yet definitive.
This is a preclinical proof-of-concept study demonstrating that a small peptide activator of the Anaphase Promoting Complex (APC) restores chemosensitivity to multidrug-resistant MDA-MB-231 breast cancer cells in vitro and in a single mouse xenograft model. The work presents mechanistic evidence (mitotic catastrophe, DNA damage, apoptosis) but lacks human efficacy data, comparative controls, and specificity testing needed to assess potential for clinical translation.
Preclinical proof-of-concept study: in vitro cell assays and in vivo mouse xenograft model. Multidrug-resistant MDA-MB-231 human breast cancer cells; in vivo studies in a mouse model.. Intervention: Small APC-activating peptides (discovered via yeast 2-hybrid screen for Apc10 interaction); one peptide tested in cells and mouse model..
APC-activating peptides increased APC activity as shown by reduced APC protein substrate levels and increased phosphorylation of APC1 S355 One peptide significantly restored chemosensitivity to MDA-MB-231 breast cancer cells both in vitro and in an in vivo mouse model Peptide treatment induced mitotic catastrophe, increased DNA damage, and activated apoptotic pathways in MDR breast cancer cells
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This finding is early-stage mechanistic work suggesting APC activation may be a strategy to restore drug sensitivity in resistant breast cancer. Clinical application is not yet supported by efficacy data, safety studies, or human trials, and further validation in additional resistant cancer models and cell lines is needed before consideration for development.
A single-arm, proof-of-concept study in cell lines and one mouse model showing mechanistic restoration of chemosensitivity in a drug-resistant breast cancer line, with clear biological signals but lacking comparative controls and human efficacy data.
As stated by the source record.
Quoted from the source exactly as published.
This finding is early-stage mechanistic work suggesting APC activation may be a strategy to restore drug sensitivity in resistant breast cancer. Clinical application is not yet supported by efficacy data, safety studies, or human trials, and further validation in additional resistant cancer models and cell lines is needed before consideration for development.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Abstract. The primary care of cancer patients involves improving their outcomes, resulting in longer remission periods and, in some cases, cures. However, many cancers eventually return to a state that is too resistant to therapy. Once cancers become multidrug resistant (MDR) and aggressive, palliative care or more toxic therapies are the remaining options for this growing population of cancer survivors. New approaches to resensitize MDR malignancies to nontoxic therapies are critically important to improve patient outcomes. Previously, we reported that activation of the Anaphase Promoting Complex (APC) resensitized recurrent MDR malignancies in vitro, independent of cancer type, chemotherapy exposure, or species. Specifically, the indirect APC chemical activator, M2I-1, resensitized MDR canine lymphoma cells and human breast cancer cells to first-line therapy. In this study, we applied small peptides that were discovered via a yeast 2-hybrid screen for peptides that interact with the Apc10 APC subunit as direct activators of the APC. The tested peptides indeed increased APC activity, as indicated by reduced APC protein substrate levels, increased (activating) phosphorylation of APC1 S355, and increased E3 ligase activity, as determined via in vitro ubiquitination assays. One peptide significantly restored chemosensitivity to the MDA-MB-231 breast cancer cell line in vitro and in an in vivo mouse model. The peptides induced mitotic catastrophe, increased DNA damage, and activated apoptotic pathways. Taken together, our results demonstrate that direct activation of the APC via a small APC-activating peptide has anticancer effects both in vitro and in vivo in MDR breast cancer cells, suggesting the potential for targeted treatment to improve patient outcomes.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.